Corvus Pharmaceuticals/$CRVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Ticker

$CRVS
Primary listing

Industry

Biotechnology

Employees

31

ISIN

US2210151005

CRVS Metrics

BasicAdvanced
$328M
-
-$0.99
0.66
-

What the Analysts think about CRVS

Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.

Bulls say / Bears say

Corvus Pharmaceuticals' lead candidate, soquelitinib, has demonstrated favorable safety and efficacy in Phase 1 trials for atopic dermatitis, with earlier and deeper responses observed in the latest cohort. (Corvus Pharmaceuticals Press Release)
The company has initiated a Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL), indicating progress towards potential market approval. (Corvus Pharmaceuticals Press Release)
Analysts at Oppenheimer have raised their price target for Corvus Pharmaceuticals to $17.00, reflecting confidence in the company's growth prospects. (ETF Daily News)
Corvus Pharmaceuticals reported a net loss of $12.1 million for Q4 2024, indicating ongoing financial challenges. (Corvus Pharmaceuticals Press Release)
StockNews.com downgraded Corvus Pharmaceuticals to a 'sell' rating, suggesting concerns about the company's future performance. (ETF Daily News)
Despite positive trial results, the company's stock price has experienced volatility, with a recent downgrade potentially impacting investor confidence. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 14 Jul 2025.

CRVS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRVS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRVS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs